Trials / Completed
CompletedNCT01063816
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors
A Phase 1 Study of Veliparib in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose of veliparib (ABT-888)and to establish the recommended Phase 2 dose of veliparib (ABT-888) when administered in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | veliparib (ABT-888) | Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method. |
| DRUG | carboplatin | Carboplatin will be dosed on Day 1 of each cycle, intravenously. |
| DRUG | gemcitabine | Dosing on Days 1 and 8 of each Cycle, intravenously. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2010-02-05
- Last updated
- 2021-08-02
Source: ClinicalTrials.gov record NCT01063816. Inclusion in this directory is not an endorsement.